Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 14/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 3/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29458332 | 0.95 | SYK (0.40) | NR1H4RXFP1RORCSYK | |
| SCHEMBL22348650 | 0.87 | NR1H4 (0.44) | NR1H4KDM4ELMNAHTTSMN1; SMN2 | |
| SCHEMBL22348736 | 0.83 | NR1H4 (0.40) | NR1H4 | |
| SCHEMBL29458307 | 0.79 | NR1H4 (0.68) | NR1H4 | |
| SCHEMBL22347328 | 0.79 | NR1H4 (0.42) | NR1H4 | |
| SCHEMBL31608465 | 0.77 | NR1H4 (0.43) | NR1H4 | |
| SCHEMBL22353515 | 0.76 | USP2 (0.40) | NR1H4 | |
| SCHEMBL22348628 | 0.75 | NR1H4 (0.37) | NR1H4 | |
| SCHEMBL29458342 | 0.74 | NR1H4 (0.42) | NR1H4 | |
| SCHEMBL29458322 | 0.74 | NR1H4 (0.38) | NR1H4SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319676-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-06-03 | — | — | US | disclosed |
| US-20220081430-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319676-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | NR1H4, FXR1, NR1H3 | NR1H4 1/4885RXFP1 10/4885RORC 71/4885 |
| US-20220081430-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885RXFP1 11/4885RORC 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.